NASDAQ

Voyager Therapeutics, Inc. (VYGR)

331 Thanks from members

Voyager Therapeutics (VYGR) garners a bullish consensus driven by its innovative TRACER platform and robust clinical progress in Alzheimer's disease treatments like VY1706 and VY7523, though bears caution over rising financial burns and variable quarterly revenue.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →